Medical innovator PixCell Medical has announced the appointment of Dr. David Stein as Chairman of its Board. Together with the members of the Board of Directors, Dr. Stein will aim to accelerate the PixCell business, scale its commercialization, and grow its operations, partnerships, and reach.
"David is a prized addition to PixCell given his strong focus on people, culture, and team development, as well as his demonstrated ability to lead company strategy globally in the field of diagnostics," said PixCell Medical CEO and co-founder Avishay Bransky. "Given David's extensive experience leading and directing engineering activities for several central lab, point-of-care, and informatics products, he is a real asset for PixCell."
Dr. Stein has held a range of leadership roles in medical companies, including a multi-faceted career at Siemens Healthineers. There, his roles included Global Head of Strategy, President of Molecular Diagnostics, CEO of the Point of Care Business, and head of strategy for the Diagnostics Division.
"PixCell Medical's HemoScreen platform is the only hematology analyzer FDA-cleared for point-of-care use that can deliver the full 5-part differential CBC with comprehensive abnormal cell flagging within six minutes," said Dr. Stein. "I have been in the diagnostics space and understand which products are poised to have the greatest impact. The HemoScreen, which leverages machine vision and PixCell's patented Viscoelastic Focusing technology, provides rapid, lab-accurate results, changing how this essential diagnostic insight is delivered across the care continuum, from the ICU to primary care, oncology, and more. I am proud to be a part of this cutting-edge enterprise at this critical time in its development."